Introduction
The Indian pharmaceutical companies have a wide variety of experience in manufacturing as per global standards. Due to intensive competition in the Indian market, Indian companies are experienced in the manufacturing of a variety of formulations that make them efficient and competitive in their operations. The Indian Pharmaceutical Industry is the 3 rd largest pharmaceutical market in terms of volume and 10 th largest in terms of value, contributing towards 10% of global production 1 . The pharmaceutical Industry in India has remained on a strong growth trajectory, over the past few years, and is expected to increase to USD 48 billion by 2017-18 at a CAGR of 14% 2 . Mergers and Acquisitions (M&A) are among the most effective ways to expedite the implementation of a plan to grow rapidly. The Indian Pharmaceutical Industry is witnessing increased M&A activities from domestic and international players which will help to boost R&D expenditure to achieve economies of scale and to strengthen the marketing network at a lightning speed. The impact of technology and the internet has further increased the pace and size of deals. and value creation in the present scenario. Samra Chaudary and Asif Sarwar, (2015) 8 determined the shareholders' wealth of the acquirer U. S. pharmaceutical companies after M&A. Santosh Kumar Sahu and Nitika Agarwal, (2015) 9 observed that M&A were common strategies of firms to increase the performance and also brought to the fore the factors affecting M&A activities in the Indian pharmaceutical sector.
Objective of the Study
• To evaluate the impact of Mergers and Acquisitions on the profitability of the select Indian pharmaceutical companies.
Methodology
The present study is based on eight pharmaceutical companies listed under BSE which involved in M&A activities in India after recession period i. The period of study comprising five financial year before-merger and after-merger for the select 8 companies ranged between 2003-04 and 2015-16.
Tools of Analysis
• Profitability ratios were computed and compared between pre and post-merger periods.
• The statistical tools namely Mean, Standard Deviation, Co-efficient of Variation and Paired't' test were employed in this research.
Impact on Profitability

Return on Total Assets
The Return on Total Assets (ROTA) ratio measures a company's Earnings Before Interest and Taxes (EBIT) against its total net assets. Higher the ratio, better the company has effectively utilized its assets to earn profit. In order to determine the impact of M&A on the return on total assets in respect of the select pharmaceutical companies the following null hypothesis was framed. H 0 : There is no significant difference in the return on total assets ratio between before and after-merger periods in respect of the select companies. Ltd. respectively. Hence, it can be comprehended that the return on total assets in case of Strides Shasun Ltd. was the highest but with highest volatility (Net sales had glided up by 137% during FY 2015-16 over the preceding year due to a significant surge in the regulated market.), while it was at the lowest with the least volatility in case of Sequent Scientific Ltd.
The result of paired't' test shows that null hypothesis is accepted in case of the companies-Strides Shasun Ltd., Sri Krishna Pharmaceuticals Ltd., Makers Labs Ltd. and IPCA Labs Ltd. and hence there is no significant difference in the return on total assets ratio between before and aftermerger periods. On the other hand, the null hypothesis is rejected in case of the companies-SMS Pharmaceuticals Ltd., Sequent Scientific Ltd., Abbott India Ltd. and Aarti Drugs Ltd. and therefore there is a significant difference in the return on total assets ratio between before and aftermerger periods.
Return on Capital Employed
The return on capital employed (ROCE) ratio shows the earning power of the capital invested in the business. It indicates how the management has used the funds supplied by creditors and owners. The higher the ratio, the more efficient is the enterprise in using funds entrusted to it. In order to determine the impact of M&A on the return on capital employed in respect of the select pharmaceutical companies, the following null hypothesis was framed. H 0 : here is no significant difference in the return on capital employed ratio between before and after-merger periods in respect of the select companies. Table 2 shows that the mean value of return on capital employed during before-merger period was at the highest at 0.497 in case of Abbott India Ltd., followed by 0.167, 0.157, 0.118, 0.098, 0.053, 0.008 and -0.019 as registered by Sequent Scientific Ltd., IPCA Labs Ltd., SMS Pharmaceuticals Ltd., Makers Labs Ltd., Aarti Drugs Ltd., Strides Shasun Ltd., and Sri Krishna Pharmaceuticals Ltd. respectively. The co-efficient of variation of the return on capital employed during the same period was at the lowest at -144.941 in case of Sri Krishna Pharmaceuticals Ltd., followed by 13.665, 16.367, 33.853, 70.863, 88.768, 112.291 and 1004.62 as registered by SMS Pharmaceuticals Ltd., Abbott India Ltd., IPCA Labs Ltd., Aarti Drugs Ltd., Sequent Scientific Ltd., Makers Labs Ltd. and Strides Shasun Ltd. respectively. Hence, it can be construed that during before-merger period the return on capital employed in case of Abbott India Ltd., was the highest with mild volatility, while it was consistently at the lowest with negative return in case of Sri Krishna Pharmaceuticals Ltd.
When observed during after-merger period the mean value of the return on capital employed was at the highest at 0.522 in case of Strides Shasun Ltd., followed by 0.413, 0.182, 0.091, 0.063, 0.002, 0.001 and -0.181 as registered by Abbott India Ltd., IPCA Labs Ltd., Aarti Drugs Ltd., Makers Labs Ltd., Sri Krishna Pharmaceuticals Ltd., SMS Pharmaceuticals Ltd. and Sequent Scientific Ltd. respectively. The co-efficient of variation of the return on capital employed during the same period was at the lowest at -147.509 in case of Sequent Scientific Ltd., followed by 7.752, 37.193, 57.048, 155.027, 204.86, 913.895 and 2789.89 as registered by Abbott India Ltd., IPCA Labs Ltd., Aarti Drugs Ltd., Makers Labs Ltd., Strides Shasun Ltd., Sri Krishna Pharmaceuticals Ltd. and SMS Pharmaceuticals Ltd. respectively. Hence, it can be perceived that during after-merger period, the return on capital employed in case of Strides Shasun Ltd. was the highest with higher volatility, while it was consistently at the lowest with negative return in case of Sequent Scientific Ltd.
The result of paired 't' test shows that the null hypothesis holds good in case of six out of eight companies with the exception of SMS Pharmaceuticals Ltd. and Sequent Scientific Ltd. Hence, it is concluded that there is no significant difference in the return on capital employed ratio between before and after-merger periods of the six out of eight select companies namely, Strides Shasun Ltd., Sri Krishna Pharmaceuticals Ltd., Makers Labs Ltd., Abbott India Ltd., Aarti Drugs Ltd. and IPCA Labs Ltd. On the other hand, there is a significant difference in the return on capital employed ratio between before and aftermerger periods of the two remaining companies-SMS Pharmaceuticals Ltd. and Sequent Scientific Ltd.
Key Findings
Impact on Profitability-ROTA
• During before-merger period, the return on total assets in case of Abbott India Ltd. was the highest and as well consistent (Mean 27.535 with CV 7.413%), while it was at the lowest and highly volatile in case of Strides Shasun Ltd. (Mean 2.064 with CV 320.56%).
• During after-merger period, the return on total assets in case of Strides Shasun Ltd. was the highest with the highest volatility (Mean 36.189 with CV 199.74%), while the same for Sequent Scientific Ltd. was negative and the lowest with the least volatility (Mean -5.707 withCV -266.638%).. • According to paired 't" test, there is a significant difference in the return on total assets ratio between before and after-merger periods for SMS Pharmaceuticals Ltd., Sequent Scientific Ltd., Abbott India Ltd. and Aarti Drugs Ltd. as the null hypothesis is rejected, while there is no sig nificant difference in case of the remaining four companies..
Impact on Profitability-ROCE
• During before-merger period, the return on capital employed in case of Abbott India Ltd., was the highest with mild volatility (Mean 0.497 with CV 16.367%), 
Conclusion
The analysis of the impact of M&A on profitability of the eight select Indian pharmaceutical companies has divulged that in case of SMS Pharmaceuticals Ltd. and Sequent Scientific Ltd., there was a significant difference in terms of both ROTA and ROCE between before-merger and aftermerger periods (Ho rejected), while in case of Abbott India Ltd. and Aarti Drugs Ltd. there was a significant difference in terms of ROTA alone between before-merger and aftermerger periods (Ho rejected). Hence this analysis confirms the need to act meticulously by the select Indian pharmaceutical companies to increase their profitability position in future, i.e. after merger.
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